By inhibiting the progression of non-alcoholic steatohepatitis (NASH) and inducing apoptosis in HepG2 cells through caspase-3 activation, canagliflozin demonstrated anti-steatotic and anti-inflammatory properties (Jojima et al. 2019). This evidence concerns the gene CASP3 and metabolic dysfunction-associated steatohepatitis.